DiaMedica Therapeutics (DMAC) Stock Price, Quote, News & History | Benzinga

DiaMedica Therapeutics Inc (DMAC) Stock Price, Quote, News & History

DMACNASDAQ

Trade with Public

Trade with Public

$6.39

-0.36-5.33%

At close: Aug 27, 5:00 PM EST

$6.75

N/A

Pre-Market: 4:01 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$6.39

Volume / Avg.

0 / 192.02K

Day Range

- - -

52 Wk Range

5.14 - 10.42

Market Cap

$364.00M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

41

Short Interest

14.8%

Days to Cover

37.85

Recent DiaMedica Therapeutics Inc News

Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrollment of first patient in phase 3 trial.

Avi Kapoor

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings

DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday.

Avi Kapoor

Why Ericsson Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Avi Kapoor

DiaMedica Raises $37.5M Via Equity Offering, Aiding Development Activities For DM199

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has entered into an agreement with accredited investors that have agreed to provide up to $37.5 million in gross proceeds through a

Nabaparna Bhattacharya

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-31.51M

Investing Cash Flow (TTM)

-11.64M

Financing Cash Flow (TTM)

44.17M

Free Cash Flow (TTM)

-31.54M

Capital Expenditure (TTM)

-33.00K

Net Change in Cash (TTM)

1.02M

Analyst Trends and Forecast

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$302.34M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

9.02

Earnings Yield % (TTM)

-11.23%

Earnings Yield % (FWD)

-12.52%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.71

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$11.00K

Total Cash

$5.13M

Debt to Equity

0.00

Issuance of Debt (TTM)

-$11.00K

Repayment of Debt (TTM)

-$11.00K

Key Statistics

Open

-

Close

$6.39

Volume / Avg.

0 / 192.02K

Day Range

- - -

52 Wk Range

5.14 - 10.42

Market Cap

$364.00M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

41

Short Interest

14.8%

Days to Cover

37.85

About

Sector

Health Care

Industry

Biotechnology

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main prod...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy DiaMedica Therapeutics (DMAC) stock?

A

You can purchase shares of DiaMedica Therapeutics (NASDAQ:DMAC) through any online brokerage.

View our list of the best stock brokerages

Q

Who are DiaMedica Therapeutics (DMAC) competitors?

A

Other companies in DiaMedica Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for DiaMedica Therapeutics (DMAC) stock?

A

DiaMedica Therapeutics has a consensus price target of $12.67.

Q

What is the current price for DiaMedica Therapeutics (DMAC)?

A

The stock price for DiaMedica Therapeutics (NASDAQ: DMAC) is $6.75 last updated August 27, 2026 at 4:00 PM EDT.

Q

Does DiaMedica Therapeutics (DMAC) pay a dividend?

A

There are no upcoming dividends for DiaMedica Therapeutics.

Q

When is DiaMedica Therapeutics (NASDAQ:DMAC) reporting earnings?

A

DiaMedica Therapeutics does not have any upcoming earnings scheduled.

Q

Is DiaMedica Therapeutics (DMAC) going to split?

A

There is no upcoming split for DiaMedica Therapeutics.

Q

What sector and industry does DiaMedica Therapeutics (DMAC) operate in?

A

DiaMedica Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.